Palopegteriparatide Improves Skeletal Dynamics in Adults With Chronic Hypoparathyroidism: 162-week Results From the Phase 2 PaTH Forward Trial

作者：Elena Tsourdi, Michael R. Rubin, Aliya Khan, Peter Schwarz, Imran Ahmed, Andrea Palermo, Filomena Cetani, Uberto Pagotto, Rajesh Jain, Chengfa Zhao, Michael S. Ominsky, B. Lai, J. Ukena, Aimee Shu, Lars Rejnmark · 发表于：Osteologie/Osteology · 年份：2025 · DOI：10.1055/s-0045-1804971 · 被引用次数：2 · 研究领域：Infrared Thermography in Medicine

Introduction: Chronic hypoparathyroidism is associated with low bone remodeling that predisposes to increased bone mineral density (BMD) due to the missing physiological effects of parathyroid hormone (PTH). Palopegteriparatide (YORVIPATH; TransCon PTH) is approved by the European Commission as a PTH replacement therapy for adults with chronic hypoparathyroidism. This analysis investigated skeletal endpoints in response to treatment with palopegteriparatide through week 162 of the PaTH Forward trial. Methods: PaTH Forward is a phase 2, randomized, double-blind, placebo-controlled 4-week trial followed by an ongoing 210-week open-label extension period. Serum bone turnover markers (BTM) of bone formation (procollagen type 1 N-terminal propeptide [P1NP]) and bone resorption (C-terminal telopeptide of type 1 collagen [CTx]) and BMD measured by DXA at the lumbar spine, total hip, femoral neck, and 1/3 distal radius were assessed at baseline and at regular intervals through week 162 Results: At baseline, participants enrolled in PaTH Forward (N=59) had a median (range) duration of hypoparathyroidism of 9 (1-39) years; mean (SD) age was 50 (12) years, and 81% were female. Fifty-seven (97%) participants continued to receive palopegteriparatide treatment through week 162 of the trial. At week 162, 52 (91%) participants achieved independence from conventional therapy (≤600 mg/day oral calcium and no active vitamin D); mean serum calcium remained in the normal range (8.3-10.6 mg/dL) fr...